Overview

In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.

Eligibility

Inclusion Criteria:

• Subjects with relapsed/refractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to autologous stem cell transplant
• ECOG 0-2
• Women of reproductive age who agree on getting a contraceptive method
• Subjects who fulfill Lugano´s criteria for disease activity
• Subjects who voluntarily accept to participate in this study

Exclusion Criteria:

• Active bacterial, viral or fungal infection
• Subjects who have already received an autologous o allogeneic stem cell transplantation
• Subjects with other active neoplasias
• Subjects with end-stage failure